When people first begin learning about cannabis, they are often introduced to the two most familiar cannabinoids: cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). These are often called “major cannabinoids” because they are typically found in greater amounts in the cannabis plant and have been the focus of more research and public attention. But the cannabis plant is much more complex than CBD and THC alone.
As cannabis science has advanced, researchers have identified more than 120 additional phytocannabinoids produced by Cannabis sativa L. These are often referred to as “minor cannabinoids” because they tend to appear in smaller concentrations compared to CBD and THC. However, “minor” does not mean unimportant. It simply means they are less abundant and, in many cases, less studied.
Understanding minor cannabinoids can help individuals become more informed consumers, especially when comparing full-spectrum, broad-spectrum, or cannabinoid-specific products. It can also help explain why two CBD products may feel different from one another, even when they contain the same amount of CBD.
How major cannabinoid discovery opened the door
Important advancements in cannabis pharmacology came with the isolation and study of CBD and THC. These discoveries helped scientists better understand how compounds from the cannabis plant interact with the body’s endocannabinoid system, including cannabinoid receptors and other molecular targets.
From there, the field expanded. Researchers began looking more closely at lesser-known compounds such as cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), cannabidivarin (CBDV), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV). Realm of Caring has previously covered several of these cannabinoids and their potential roles in product formulation, inflammation, sleep, mood, and neurological health.
The growing interest in minor cannabinoids is also showing up in the research literature. A 2025 systematic review on minor cannabinoids and psychiatric disorders noted that while CBD and THC are more extensively researched, approximately 120 minor cannabinoids have been identified. The review found that some compounds show promising pharmacological profiles, but emphasized that the research remains early and fragmented, especially in clinical settings.
Acidic cannabinoids: the plant’s natural starting point
One of the most helpful ways to understand cannabinoids is to know that many begin in an acidic form.
When the cannabis plant is growing, cannabinoids are typically present as cannabinoid acids. These acidic cannabinoids are often considered precursor compounds, meaning they can convert into the more familiar “neutral” cannabinoids through a process called decarboxylation. Decarboxylation can happen with heat, time, drying, curing, smoking, vaporizing, or cooking.
For example:
- CBGA may convert into CBG.
- THCA may convert into THC.
- CBDA may convert into CBD.
- CBCA may convert into CBC.
CBGA is often referred to as a “mother cannabinoid” because enzymes in the plant convert it into major cannabinoid acids such as THCA, CBDA, and CBCA. Once exposed to heat, CBGA may convert into CBG. Because CBGA is used by the plant to make so many other compounds, only small amounts of CBG are usually found in many cannabis varieties.
Acidic cannabinoids are not simply inactive placeholders. They may have their own properties and potential benefits before decarboxylation. For example, CBDA has been studied for anti-inflammatory activity and nausea-related pathways, although more research is needed to understand how these findings translate into human use.
This is one reason a product’s certificate of analysis matters as a part of your product checklist. A label that lists “CBD” may not tell the whole story if the product also contains CBDA, CBG, CBGA, or other acidic cannabinoids.
Varin cannabinoids: small structural differences, different effects
Another category to know is the varin cannabinoids. These include compounds such as THCV, CBDV, CBGV, and CBCV. Varins are similar to their non-varin counterparts, but they have a shorter carbon side chain. Traditional cannabinoids generally have a five-carbon side chain, while varin cannabinoids have a three-carbon side chain.
That may sound like a small chemistry detail, but small structural differences can change how a cannabinoid behaves in the body.
THCV is a good example. While it has a name that looks similar to THC, it is not the same compound and does not necessarily behave like THC. In one study examining minor cannabinoids at the CB1 receptor, researchers found that Δ9-THCV antagonized the CB1 receptor in an isomer- and ligand-dependent manner. In simpler terms, THCV may interact with cannabinoid signaling in a way that is meaningfully different from THC, depending on the context.
CBDV is another varin cannabinoid receiving attention. It is non-intoxicating and has been studied in areas such as seizure activity, nausea, inflammation, and neurodevelopmental conditions. The 2025 systematic review also noted CBDV among compounds investigated in preclinical and limited clinical research for psychiatric or neurodevelopmental relevance.
Why this matters when choosing a product
As more products enter the market, consumers are seeing labels that highlight CBG, CBN, CBC, THCV, CBDV, CBDA, or full-spectrum “cannabinoid blends”. This can be helpful, but it can also be confusing.
A cannabinoid profile can give clues about what a product was designed to support. For example, a product marketed for sleep may include CBD with CBN or calming botanical ingredients. A product designed for daytime use may include CBD with CBG or CBC. A product focused on preserving the plant’s raw compounds may contain CBDA or CBGA.
However, product choice should not be based on marketing alone. Individuals should look for transparent testing, a certificate of analysis, clear serving sizes, and support from knowledgeable professionals. This is especially important for individuals taking medications, managing chronic conditions, caring for children, or supporting aging adults.
The more we understand the cannabis plant, the more we see that it is not one compound, one outcome, or one-size-fits-all. CBD and THC opened the door to cannabinoid science. Minor cannabinoids are helping us understand the many ways this plant’s components may work together, and why individualized education remains essential.
For help understanding cannabinoid profiles, sourcing quality products, or deciding what questions to ask before beginning, Realm of Caring’s care team is available to provide free guidance.
